{"id":17824,"date":"2026-07-08T11:11:15","date_gmt":"2026-07-08T11:11:15","guid":{"rendered":"https:\/\/www.eyecliniclondon.com\/blog\/?p=17824"},"modified":"2026-07-08T11:11:15","modified_gmt":"2026-07-08T11:11:15","slug":"anchor-study-wet-amd-treatment","status":"publish","type":"post","link":"https:\/\/www.eyecliniclondon.com\/blog\/anchor-study-wet-amd-treatment\/","title":{"rendered":"The ANCHOR Study: A Turning Point in Wet Macular Degeneration Treatment"},"content":{"rendered":"

Wet age-related macular degeneration (AMD) is one of the most serious causes of vision loss in older adults. If you have wet AMD, abnormal blood vessels can grow beneath the retina and leak fluid or blood into the macula, the central part of your retina responsible for detailed vision. Unlike dry AMD, which often develops more gradually, wet AMD can cause rapid changes in your central vision and significantly affect activities such as reading, driving, and recognising faces.<\/p>\n

For many years, treatment options for wet AMD were limited and mainly focused on slowing further damage rather than restoring or improving vision. The introduction of anti-vascular endothelial growth factor (anti-VEGF) therapy completely changed the approach to managing wet AMD. These treatments target VEGF, a protein that promotes abnormal blood vessel growth and leakage, helping many patients preserve and, in some cases, improve their sight.<\/p>\n

One of the most influential clinical trials that helped establish this new era of treatment was the ANCHOR Study. This landmark research evaluated the effectiveness of ranibizumab, an anti-VEGF medication, in people with wet AMD and demonstrated that targeted VEGF inhibition could significantly improve visual outcomes compared with earlier treatment approaches.<\/p>\n

The findings from ANCHOR helped reshape retinal medicine and contributed to establishing anti-VEGF therapy as a standard treatment approach for wet AMD for wet AMD. If you are diagnosed with wet AMD today, your ophthalmologist can use the evidence from studies like ANCHOR to guide treatment decisions and develop a personalised plan designed to protect your vision over the long term.<\/p>\n

What Was the ANCHOR Study?<\/h2>\n

The ANCHOR Study was a major clinical trial that investigated the effectiveness of ranibizumab, an anti-VEGF medication, in treating wet age-related macular degeneration (AMD). If you have wet AMD, the findings from this landmark study are highly relevant because they helped establish the treatments that are widely used to protect vision today.<\/p>\n

Researchers compared ranibizumab injections with an older treatment approach known as verteporfin photodynamic therapy (PDT). The aim of the study was to determine whether anti-VEGF treatment could provide better visual outcomes by reducing abnormal blood vessel growth and leakage beneath the retina.<\/p>\n

The results showed that ranibizumab offered significant benefits for many patients with wet AMD and represented a major advancement in retinal medicine. The ANCHOR Study helped change the direction of retinal care by helping establish anti-VEGF therapy as a leading treatment approach for people with wet AMD. If you are diagnosed with this condition, your ophthalmologist can use evidence from studies like ANCHOR to guide a treatment plan tailored to your individual vision needs.<\/p>\n

Why Was the Study Important?<\/h2>\n

Before anti-VEGF treatments became widely available, wet age-related macular degeneration (AMD) was often associated with progressive and irreversible vision loss. If you developed wet AMD during this period, treatment options were limited and were generally focused on slowing further damage rather than actively improving your vision.<\/p>\n

Existing treatments, such as verteporfin photodynamic therapy (PDT), could help reduce disease activity in some patients but were less likely to restore lost vision. Researchers recognised the need for more effective treatments that could directly target the biological processes responsible for abnormal blood vessel growth and leakage beneath the retina.<\/p>\n

The ANCHOR Study provided important evidence for a major breakthrough in wet AMD treatment. By demonstrating the effectiveness of ranibizumab, the study helped introduce a new era of anti-VEGF therapy and transformed the way ophthalmologists manage wet AMD. Today, if you are diagnosed with wet AMD, modern anti-VEGF treatment may help preserve vision and can improve visual acuity in some patients<\/p>\n

Understanding Wet Age-Related Macular Degeneration<\/h2>\n

Wet age-related macular degeneration (AMD) occurs when abnormal blood vessels grow beneath the retina, particularly in the area around the macula. If you have wet AMD, these fragile blood vessels can leak fluid or blood, causing swelling and damage to the macula, the central part of your retina responsible for sharp, detailed vision.<\/p>\n

Because the macula controls your central vision, damage in this area can affect important daily activities such as reading, recognising faces, driving, and seeing fine details clearly. Unlike dry AMD, which often progresses more slowly, wet AMD can cause rapid changes in your vision and requires prompt medical attention.<\/p>\n

Early diagnosis and treatment are essential for protecting your sight. If you notice symptoms such as blurred central vision, distorted lines, or a sudden change in your ability to see details, an eye examination with an ophthalmologist can help identify wet AMD quickly and allow appropriate treatment to begin as soon as possible. Regular monitoring also plays an important role in maintaining your long-term eye health.<\/p>\n

The Role of VEGF in Wet AMD<\/h2>\n

Vascular endothelial growth factor (VEGF) is a protein that plays an important role in the growth and development of blood vessels. In wet age-related macular degeneration (AMD), increased VEGF activity can cause abnormal blood vessels to grow beneath the retina.<\/p>\n

These fragile, abnormal vessels are prone to leaking fluid and blood, which can lead to swelling, damage to the macula, and loss of central vision. If you have wet AMD, controlling VEGF activity is a key part of preventing further retinal damage and protecting your sight.<\/p>\n

Anti-VEGF medications work by blocking the effects of VEGF, helping to reduce abnormal blood vessel growth and leakage. This approach transformed the treatment of retinal disease by targeting a key pathway involved in abnormal blood vessel growth and leakage in wet AMD rather than simply managing its effects. The development of anti-VEGF therapy, supported by studies such as the ANCHOR Study, has given many patients a better opportunity to preserve and improve their vision.<\/p>\n

Study Design<\/h2>\n

The ANCHOR Study was a randomised, controlled clinical trial involving patients with predominantly classic choroidal neovascularisation (CNV) caused by wet age-related macular degeneration (AMD). If you had this type of wet AMD, you could take part in the study to help researchers compare the effectiveness of newer anti-VEGF treatment with existing therapy options.<\/p>\n

Participants were randomly assigned to monthly intravitreal ranibizumab at one of two doses or to verteporfin photodynamic therapy, allowing researchers to compare visual outcomes between the treatment strategies. (PDT). Researchers monitored vision outcomes over time, including changes in visual acuity, to determine how effectively each treatment helped preserve or improve sight.<\/p>\n

The structured design of the ANCHOR Study provided strong clinical evidence by allowing a direct comparison between the two treatment approaches. Its findings helped demonstrate the benefits of anti-VEGF therapy and played a major role in changing how ophthalmologists treat wet AMD today.<\/p>\n

Comparing Ranibizumab with Photodynamic Therapy<\/h2>\n

One of the main aims of the ANCHOR Study was to determine whether ranibizumab could provide better results than existing treatment options for people with wet age-related macular degeneration (AMD). Before anti-VEGF therapy became widely available, treatments such as verteporfin photodynamic therapy (PDT) were used to slow disease activity, but they were less effective at improving vision.<\/p>\n

The study showed that patients who received ranibizumab injections achieved significantly better visual outcomes compared with those who received photodynamic therapy. If you have wet AMD, this finding is important because it demonstrated that targeting VEGF could do more than simply reduce further damage; it could also help preserve and improve your sight.<\/p>\n

The results of the ANCHOR Study represented a major advancement in AMD management and changed the way ophthalmologists approached treatment. The evidence from this landmark trial helped establish anti-VEGF injections as a standard therapy for wet AMD, allowing many patients to receive more effective care tailored to their individual vision needs.<\/p>\n

Key Findings of the ANCHOR Study<\/h2>\n

The ANCHOR Study demonstrated that regular ranibizumab injections could prevent vision loss and improve vision in many patients with wet age-related macular degeneration (AMD). If you have wet AMD, these findings represent an important shift in how your condition can be managed, offering greater hope for maintaining your central vision.<\/p>\n

Before anti-VEGF treatments became available, many therapies focused mainly on slowing further deterioration rather than improving sight. The results from ANCHOR showed that targeting vascular endothelial growth factor (VEGF) could actively reduce disease activity and provide meaningful visual benefits for patients.<\/p>\n

These findings changed expectations for both patients and clinicians. The study helped establish a new standard of care for wet AMD and showed that effective treatment could do more than protect against vision loss it could also help many people achieve improvements in their vision and quality of life.<\/p>\n

Evidence Note: What Did ANCHOR Actually Find?<\/strong><\/p>\n

The ANCHOR trial enrolled 423 people with newly diagnosed, predominantly classic subfoveal choroidal neovascularisation caused by neovascular AMD.<\/p>\n

After one year, more than 94% of participants receiving monthly ranibizumab lost fewer than 15 visual-acuity letters, compared with approximately 64% of those receiving verteporfin photodynamic therapy.<\/p>\n

Meaningful visual improvement was also much more common with ranibizumab. Around 36% to 40% of patients receiving ranibizumab gained at least 15 letters, compared with fewer than 6% of patients receiving PDT.<\/p>\n

For you as a patient, the significance of these findings is that treatment expectations changed. Earlier treatments had mainly aimed to reduce the rate of further visual decline. ANCHOR showed that ranibizumab treatment could help many participants preserve vision, while a substantial proportion achieved a clinically meaningful improvement in visual acuity.<\/p>\n

Vision Improvement Results<\/h2>\n

\"\"<\/p>\n

A particularly important discovery from the ANCHOR Study was that some patients with wet age-related macular degeneration (AMD) achieved meaningful improvements in their vision. If you have wet AMD, this finding is significant because it changed the belief that treatment could only slow vision loss rather than help improve visual acuity in some patients<\/p>\n

Before anti-VEGF therapy became available, significant vision recovery was uncommon in wet AMD. Many treatments were primarily aimed at limiting further damage caused by abnormal blood vessel growth and leakage beneath the retina. The ANCHOR Study showed that by controlling vascular endothelial growth factor (VEGF) activity with ranibizumab, patients could achieve better visual outcomes.<\/p>\n

This discovery transformed patient care and changed the goals of wet AMD treatment. Today, your ophthalmologist can use anti-VEGF therapies not only to help prevent further vision loss but also to provide the possibility of visual improvement in suitable patients. The findings from ANCHOR continue to influence how wet AMD is treated worldwide.<\/p>\n

Two-Year Research Insight<\/strong><\/p>\n

The visual benefit of ranibizumab was not limited to the first year of treatment.<\/p>\n

At two years, around 90% of participants receiving monthly ranibizumab had avoided losing 15 or more visual-acuity letters, compared with approximately 66% of participants treated with verteporfin PDT.<\/p>\n

Around one-third to two-fifths of ranibizumab-treated participants had gained at least 15 letters, compared with only about 6% in the PDT group.<\/p>\n

These findings showed that the visual advantage of monthly ranibizumab over verteporfin PDT was maintained through the two-year ANCHOR study period. However, ANCHOR used a fixed monthly injection schedule, so its results should not be used to suggest that every patient today needs indefinite monthly injections. Modern treatment intervals are often adjusted according to disease activity and individual response.<\/p>\n

Clinical Insight: Vision Improvement Is Possible, but Not Guaranteed<\/strong><\/p>\n

ANCHOR changed expectations because some patients gained meaningful visual acuity after treatment. However, this does not mean that every person receiving anti-VEGF treatment will recover vision already lost. An ANCHOR subgroup analysis found that baseline vision, lesion size and age were important predictors of visual outcome.<\/p>\n

The Beginning of the Anti-VEGF Era<\/h2>\n

The ANCHOR Study helped establish anti-VEGF injections as one of the most important treatment approaches for wet age-related macular degeneration (AMD). If you have wet AMD, this breakthrough changed the options available to you by introducing a therapy that could actively target the cause of vision loss rather than only slowing disease progression.<\/p>\n

Following the results of ANCHOR, anti-VEGF treatment became widely adopted in retinal clinics around the world. If you are diagnosed with wet AMD today, your ophthalmologist may recommend anti-VEGF injections because these treatments can reduce abnormal blood vessel leakage, control retinal swelling, and help protect your central vision.<\/p>\n

The ANCHOR Study marked a new era in managing macular disease. It changed how doctors and patients viewed wet AMD treatment by showing that preserving and improving vision was possible for many people. The study continues to influence modern retinal care and remains a foundation of treatment decisions for patients with wet AMD.<\/p>\n

UK Clinical Practice Note<\/strong><\/p>\n

The principles established by ANCHOR remain highly relevant, but current UK wet AMD care has developed considerably since the trial.<\/p>\n

NICE recommends urgent referral to a macula service for suspected active wet AMD, normally within one working day. OCT should be offered as part of the assessment, and where anti-VEGF treatment is recommended for confirmed active wet AMD, NICE advises starting treatment as soon as possible and within 14 days of referral to the macular service.<\/p>\n

NICE recommends intravitreal anti-VEGF treatment for eligible active wet AMD and ongoing OCT monitoring of both eyes. Photodynamic therapy should not be offered alone for active wet AMD.<\/p>\n

For you, this means that the legacy of ANCHOR is seen not only in the use of anti-VEGF injections but also in the modern emphasis on rapid referral, prompt treatment and careful imaging-based follow-up.<\/p>\n

Treatment Involves Regular Monitoring<\/h2>\n

Although anti-VEGF therapy has transformed the treatment of wet age-related macular degeneration (AMD), you usually require ongoing monitoring and repeated treatments to maintain the benefits. Wet AMD is a chronic condition, and disease activity can return if abnormal blood vessel growth and leakage are not carefully controlled.<\/p>\n

Retinal specialists use regular vision assessments and advanced imaging technology, such as optical coherence tomography (OCT), to monitor changes within your retina. These evaluations help your ophthalmologist determine whether your eye is responding well to treatment and whether additional anti-VEGF injections are needed.<\/p>\n

Regular follow-up appointments remain essential for protecting your long-term vision. If you have wet AMD, attending scheduled reviews allows your ophthalmologist to adjust your treatment plan based on your individual response and provide the most effective care for maintaining your sight.<\/p>\n

The Importance of OCT Imaging<\/h2>\n

Modern optical coherence tomography (OCT) scans have become an essential part of managing wet age-related macular degeneration (AMD). If you have wet AMD, this advanced imaging technology allows your ophthalmologist to examine the retina in great detail and detect even small changes in fluid levels beneath the macula.<\/p>\n

OCT helps identify whether your AMD is active by showing signs of retinal swelling, fluid leakage, or other changes that may require further treatment. By monitoring these changes over time, your retinal specialist can decide whether anti-VEGF injections should continue, be adjusted, or be spaced further apart.<\/p>\n

This technology supports personalised treatment decisions by allowing your care plan to be based on the specific condition of your retina rather than a fixed schedule alone. If you are receiving treatment for wet AMD, regular OCT monitoring helps your ophthalmologist provide timely care and supports timely monitoring and appropriate treatment decisions<\/p>\n

Individual Treatment Plans<\/h2>\n

ANCHOR established the efficacy of regular ranibizumab treatment, while later studies and modern clinical practice have developed more individualised approaches to treatment frequency. Today, your ophthalmologist may use visual acuity, symptoms and OCT findings to decide whether treatment intervals should be maintained, shortened or extended.<\/p>\n

Factors such as the level of disease activity, changes within your retina, your overall health, and how well your eye responds to treatment all influence management decisions. Your ophthalmologist may adjust the frequency of injections or modify your treatment approach based on regular examinations and OCT imaging results.<\/p>\n

Personalised care supports treatment decisions based on your individual clinical findings and response by ensuring that your treatment is neither excessive nor insufficient. By combining the evidence from studies such as ANCHOR with your individual clinical findings, your retinal specialist can create a management plan designed to protect your vision over the long term.<\/p>\n

How Modern Wet AMD Treatment Is Reviewed and Adjusted<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n
Area Reviewed<\/td>\nWhat Your Ophthalmologist Looks For<\/td>\nHow It May Influence Ongoing Care<\/td>\n<\/tr>\n<\/thead>\n
Visual acuity<\/td>\nWhether your measured vision has improved, remained stable or declined<\/td>\nHelps assess the functional response to treatment<\/td>\n<\/tr>\n
OCT findings<\/td>\nChanges in retinal fluid, swelling and macular structure<\/td>\nHelps identify continuing or recurrent disease activity<\/td>\n<\/tr>\n
Visual symptoms<\/td>\nNew or worsening blur, distortion or changes in central vision<\/td>\nMay prompt earlier assessment or additional investigation<\/td>\n<\/tr>\n
Response to previous injections<\/td>\nHow well disease activity has been controlled after treatment<\/td>\nHelps guide whether the existing treatment approach remains appropriate<\/td>\n<\/tr>\n
Pattern of disease activity<\/td>\nWhether the retina remains stable or shows recurrent activity between visits<\/td>\nMay influence whether treatment intervals are maintained, shortened or extended<\/td>\n<\/tr>\n
Condition of the other eye<\/td>\nSigns of wet AMD activity or new retinal changes in the fellow eye<\/td>\nSupports early detection and appropriate management of disease affecting either eye<\/td>\n<\/tr>\n
Overall clinical assessment<\/td>\nImaging, vision, symptoms and previous response considered together<\/td>\nSupports an individualised treatment and monitoring plan<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Modern wet AMD management is more individualised than the fixed monthly injection schedule studied in ANCHOR. Your ophthalmologist considers your vision, OCT findings, symptoms and treatment response together when deciding how your treatment and monitoring plan should continue.<\/p>\n

Advances Since the ANCHOR Study<\/h2>\n

Since the ANCHOR Study transformed the treatment of wet age-related macular degeneration (AMD), retinal medicine has continued to progress. If you have wet AMD today, you benefit from years of research that have expanded treatment options and improved the way anti-VEGF therapy is delivered.<\/p>\n

New anti-VEGF medications, longer-lasting treatments, and improved injection strategies have been developed to make treatment more convenient while maintaining effective control of disease activity. These advances aim to reduce the burden of frequent appointments and provide more flexible treatment schedules for suitable patients.<\/p>\n

Research continues to improve patient experiences and long-term outcomes in wet AMD care. Your ophthalmologist can now combine evidence from landmark studies such as ANCHOR with newer developments in retinal medicine to create a personalised treatment plan that supports your vision and quality of life.<\/p>\n

Lifestyle and AMD Management<\/h2>\n

\"\"<\/p>\n

Although treatments such as anti-VEGF injections are central to managing wet age-related macular degeneration (AMD), your lifestyle choices also play an important role in supporting long-term eye health. Medical treatment works best when combined with healthy habits that help protect your overall wellbeing.<\/p>\n

Not smoking, maintaining a balanced diet rich in nutrients, exercising regularly, and managing conditions such as high blood pressure can all contribute to better eye health. Attending routine eye examinations also allows your ophthalmologist to monitor changes in your retina and identify any signs that your condition may require further attention.<\/p>\n

A complete approach to AMD management combines effective medical treatment with healthy lifestyle choices and regular monitoring. By following your personalised care plan and working closely with your ophthalmologist, you can take important steps towards protecting your vision and maintaining your quality of life over the long term.<\/p>\n

Reducing Treatment Burden<\/h2>\n

One of the challenges of anti-VEGF therapy for wet age-related macular degeneration (AMD) is the need for repeated injections and regular follow-up appointments. If you have wet AMD, ongoing treatment is often necessary to control disease activity and protect your vision, but the frequency of visits can be demanding for some patients.<\/p>\n

Researchers are now exploring longer-acting medications and sustained-release technologies that may reduce how often you need injections. These newer approaches aim to maintain effective levels of treatment inside the eye for longer periods while reducing the number of clinic appointments required.<\/p>\n

future treatments may offer greater convenience while aiming to maintain effective disease control As research continues, your ophthalmologist will be able to consider emerging therapies alongside established treatments to provide care that balances vision protection, treatment effectiveness, and your individual lifestyle needs.<\/p>\n

The Role of Early Diagnosis<\/h2>\n

Wet age-related macular degeneration can progress quickly, so early diagnosis is very important. Prompt assessment allows your ophthalmologist to detect active disease and begin treatment before further damage affects central vision.<\/p>\n